Hyperalgesia

Hyperalgesia refers to an exaggerated response to painful stimuli, representing a heightened sensitivity of the nervous system. It is a significant clinical phenomenon observed in various pain conditions, ranging from inflammation to neuropathic disorders. Understanding its mechanisms and classification is crucial for accurate diagnosis and effective management in both acute and chronic pain settings.

Introduction

Overview of Hyperalgesia

Hyperalgesia is characterized by an increased perception of pain following a stimulus that would ordinarily produce mild or moderate discomfort. This condition reflects an abnormal amplification of pain signals within the peripheral or central nervous system. It may arise from tissue injury, nerve damage, inflammation, or prolonged opioid use. Clinically, hyperalgesia contributes to the persistence and severity of pain syndromes, making it an important focus in pain medicine and neuroscience.

Definition and Clinical Relevance

Medically, hyperalgesia is defined as an enhanced pain response to a noxious stimulus. It often manifests in conditions such as burns, arthritis, neuropathies, and postoperative pain. The phenomenon indicates dysfunction in pain modulation pathways, particularly when inhibitory control is lost or excitatory pathways become sensitized. Its relevance extends to patient care, as improper recognition can lead to ineffective treatment and chronic pain progression.

Distinction Between Hyperalgesia and Allodynia

Although hyperalgesia and allodynia are both forms of abnormal pain perception, they differ fundamentally in stimulus type and response. In hyperalgesia, the pain is exaggerated in response to a normally painful stimulus, while in allodynia, pain occurs due to a stimulus that is normally non-painful, such as light touch. The following table highlights key differences between these two conditions:

Feature	Hyperalgesia	Allodynia
Stimulus Type	Noxious (painful)	Non-noxious (normally not painful)
Response	Exaggerated pain sensation	New onset of pain from innocuous stimuli
Mechanism	Peripheral or central sensitization	Central sensitization, altered sensory processing
Common Examples	Inflammatory pain, burn injury, neuropathic pain	Fibromyalgia, neuropathy, postherpetic neuralgia

Historical Background and Evolution of the Concept

The concept of hyperalgesia has evolved through centuries of pain research. Early observations of increased pain sensitivity following injury were documented in the 19th century, but the neurophysiological mechanisms became clearer only in the late 20th century with advances in neurobiology. The identification of peripheral and central sensitization processes provided a foundation for understanding how hyperalgesia develops and persists in chronic pain states. Modern research continues to explore the molecular and cellular pathways involved, paving the way for targeted therapies.

Physiological Basis of Pain Perception

Normal Pain Pathways

Under normal conditions, pain serves as a protective mechanism, alerting the body to potential harm. Nociceptive signals originate from specialized sensory neurons called nociceptors, which detect thermal, mechanical, or chemical damage. These signals are transmitted via A-delta and C fibers to the dorsal horn of the spinal cord, then relayed through ascending pathways such as the spinothalamic tract to the brain for perception and interpretation. The experience of pain is modulated by descending inhibitory pathways, ensuring balance between protection and overreaction.

Role of Nociceptors

Nociceptors are free nerve endings present in skin, muscles, joints, and viscera. They respond to potentially damaging stimuli by generating action potentials that signal pain. There are two main types of nociceptors: A-delta fibers, which transmit fast, sharp pain, and C fibers, responsible for dull, burning pain. When activated repeatedly or exposed to inflammatory mediators, nociceptors become sensitized, leading to a lowered threshold for activation and enhanced pain response—an essential mechanism in hyperalgesia.

Peripheral and Central Sensitization Mechanisms

Hyperalgesia arises primarily through sensitization processes occurring at both peripheral and central levels. Peripheral sensitization occurs when nociceptors in injured or inflamed tissue exhibit increased responsiveness due to chemical mediators like prostaglandins, bradykinin, and cytokines. Central sensitization, on the other hand, involves enhanced excitability of neurons in the spinal cord and brain, often mediated by glutamate and NMDA receptor activation. Together, these mechanisms lead to abnormal amplification of pain signals, even after the initial injury has healed.

Types of Hyperalgesia

Primary Hyperalgesia

Primary hyperalgesia occurs at the site of tissue injury or inflammation. It is characterized by an increased sensitivity of nociceptors within the damaged area, primarily due to local release of inflammatory mediators such as prostaglandins, bradykinin, and substance P. This localized hypersensitivity serves a biological purpose by protecting the injured tissue from further harm, though it can also contribute to prolonged discomfort in clinical conditions.

Secondary Hyperalgesia

Secondary hyperalgesia develops in the uninjured tissue surrounding or distant from the site of injury. Unlike primary hyperalgesia, it is mediated predominantly by central sensitization mechanisms within the spinal cord and brain. The phenomenon is marked by an increased responsiveness of central neurons to input from both damaged and undamaged peripheral fibers, often resulting in widespread or referred pain.

Dynamic vs Static Hyperalgesia

Dynamic hyperalgesia refers to heightened pain perception during movement or light brushing over the skin, whereas static hyperalgesia occurs when a constant or sustained stimulus causes exaggerated pain. Dynamic hyperalgesia is often associated with central nervous system sensitization, while static forms tend to involve peripheral sensitization at the site of injury.

Thermal, Mechanical, and Chemical Hyperalgesia

Hyperalgesia can also be categorized based on the type of stimulus that elicits the exaggerated response:

• Thermal Hyperalgesia: Increased sensitivity to heat or cold stimuli, commonly observed in burn injuries or neuropathic pain.
• Mechanical Hyperalgesia: Enhanced pain from pressure, touch, or pinprick stimuli, typically associated with tissue inflammation or nerve compression.
• Chemical Hyperalgesia: Exaggerated response to chemical irritants such as capsaicin or histamine, mediated by activation of chemosensitive nociceptors.

Pathophysiology of Hyperalgesia

Peripheral Mechanisms

Peripheral sensitization forms the initial phase of hyperalgesia, where nociceptors in the damaged or inflamed region become more responsive. This is primarily due to biochemical and ionic changes that lower the threshold for activation. Inflammatory mediators such as prostaglandins, interleukins, bradykinin, and substance P bind to receptors on nociceptor terminals, leading to the phosphorylation of ion channels and enhanced neuronal excitability.

Nociceptor Sensitization

When tissue injury occurs, nociceptors undergo structural and functional changes. Voltage-gated sodium and calcium channels are upregulated, facilitating easier generation of action potentials. Simultaneously, TRPV1 (transient receptor potential vanilloid 1) channels become more sensitive to heat and protons, further amplifying the pain response. This increased excitability persists as long as inflammatory mediators remain present.

Inflammatory Mediators

Chemical substances released during tissue damage play a crucial role in the development of peripheral hyperalgesia. Key mediators include:

• Prostaglandins: Produced by cyclooxygenase enzymes, they sensitize nociceptors and promote vasodilation.
• Bradykinin: Enhances pain through activation of B2 receptors on sensory neurons.
• Cytokines (e.g., IL-1β, TNF-α): Contribute to the recruitment of immune cells and prolong inflammation, maintaining the sensitized state.

Ion Channel Modulation

The modulation of ion channels is central to the mechanism of peripheral hyperalgesia. TRPV1 channels mediate thermal pain, while Nav1.7 and Nav1.8 sodium channels regulate neuronal excitability. Upregulation or phosphorylation of these channels reduces the activation threshold, resulting in spontaneous firing and pain amplification. These molecular changes form the foundation for drug targets in pain management.

Central Mechanisms

Central sensitization is the second major component of hyperalgesia. It involves enhanced excitability and synaptic efficiency of neurons within the dorsal horn of the spinal cord and higher centers of the brain. Continuous nociceptive input from the periphery leads to an increased release of glutamate and substance P, which activate NMDA and AMPA receptors. This results in long-term potentiation-like changes in pain transmission pathways.

Role of NMDA Receptors and Glutamate

NMDA receptor activation plays a pivotal role in central hyperexcitability. Excessive glutamate release leads to calcium influx, triggering intracellular cascades that strengthen synaptic transmission. Over time, this process causes neurons to respond more intensely to subsequent stimuli, even if they are weak or non-noxious. This neuroplastic change is a hallmark of chronic pain states.

Disinhibition of Inhibitory Neurons

Under normal circumstances, inhibitory interneurons in the spinal cord release gamma-aminobutyric acid (GABA) and glycine to dampen pain transmission. In hyperalgesia, these inhibitory circuits may be disrupted, either through neuronal loss or altered receptor function, resulting in unopposed excitatory signaling. This disinhibition contributes significantly to the maintenance of central sensitization.

Glial Cell Activation and Neuroinflammation

Microglia and astrocytes within the central nervous system become activated in response to persistent nociceptive signaling. Once activated, these glial cells release pro-inflammatory cytokines, chemokines, and nitric oxide, further amplifying neuronal excitability. The interplay between neurons and glia sustains the hyperalgesic state long after the initial injury has resolved, contributing to chronic pain syndromes.

Causes and Contributing Factors

Inflammatory Conditions

Inflammation is one of the primary triggers of hyperalgesia. During an inflammatory response, immune cells such as macrophages, mast cells, and neutrophils release a cascade of chemical mediators that sensitize peripheral nociceptors. Prostaglandins, bradykinin, and cytokines like IL-6 and TNF-α contribute to the lowering of nociceptor thresholds, enhancing pain sensitivity. Common inflammatory conditions associated with hyperalgesia include rheumatoid arthritis, gout, and tissue injury following trauma or surgery.

Nerve Injury and Neuropathic Pain

Damage to peripheral nerves, whether through trauma, compression, or metabolic disorders, can lead to neuropathic pain and hyperalgesia. Injured neurons exhibit abnormal excitability and ectopic firing, resulting in persistent pain even in the absence of external stimuli. Structural and functional changes in the dorsal root ganglion and spinal cord further amplify the transmission of pain signals. Conditions such as diabetic neuropathy, postherpetic neuralgia, and sciatica commonly exhibit hyperalgesic symptoms.

Chronic Pain Syndromes

Chronic pain conditions, including fibromyalgia, complex regional pain syndrome (CRPS), and chronic low back pain, often feature hyperalgesia as a core symptom. In these syndromes, ongoing central sensitization sustains the exaggerated pain response. Psychological stress, sleep disturbances, and hormonal imbalances can further modulate pain perception, creating a self-perpetuating cycle of pain and hypersensitivity.

Opioid-Induced Hyperalgesia

Paradoxically, prolonged use of opioids for pain relief can lead to an increase in pain sensitivity, known as opioid-induced hyperalgesia (OIH). The mechanism involves neuroplastic changes within the central nervous system, including NMDA receptor activation, increased spinal dynorphin levels, and enhanced descending facilitation of pain. Recognizing OIH is critical, as increasing opioid doses may worsen pain rather than alleviate it.

Post-Surgical and Post-Traumatic Pain

Following surgical procedures or traumatic injuries, patients may experience transient or persistent hyperalgesia. Surgical incision and tissue damage activate both peripheral and central sensitization pathways. Factors such as inadequate perioperative pain control, repeated surgical interventions, and prolonged inflammation can prolong the hyperalgesic state, contributing to chronic postoperative pain syndromes.

Central Nervous System Disorders

Diseases that affect central pain modulation pathways can also precipitate hyperalgesia. Disorders such as multiple sclerosis, spinal cord injury, and stroke can disrupt inhibitory pain control mechanisms, leading to enhanced excitatory transmission. In these cases, hyperalgesia is often accompanied by other sensory disturbances, including allodynia and paresthesia.

Clinical Manifestations

Symptoms and Pain Characteristics

Patients with hyperalgesia present with an exaggerated pain response to stimuli that would normally cause mild discomfort. The pain may be described as burning, stabbing, or throbbing, and can occur spontaneously or upon physical contact. The intensity and persistence of pain often exceed the expected level for the underlying condition, reflecting heightened neural sensitivity.

Distribution and Severity Patterns

The pattern of hyperalgesia depends on its underlying cause and mechanism. Primary hyperalgesia is confined to the site of injury or inflammation, while secondary hyperalgesia may extend to surrounding or distant areas. In conditions involving central sensitization, such as fibromyalgia or neuropathic pain, the hyperalgesia may become widespread and generalized across multiple body regions.

Associated Sensory Abnormalities

Hyperalgesia often coexists with other sensory disturbances, reflecting altered somatosensory processing. These may include:

• Allodynia: Pain from normally non-painful stimuli, such as light touch or gentle pressure.
• Paresthesia: Tingling or prickling sensations in the affected area.
• Dysesthesia: Unpleasant abnormal sensations, either spontaneous or evoked.

The coexistence of these symptoms often complicates diagnosis and necessitates detailed sensory testing.

Impact on Function and Quality of Life

Hyperalgesia significantly affects a patient’s daily activities, mental health, and social well-being. Persistent pain can lead to reduced mobility, sleep disturbances, anxiety, and depression. The constant experience of pain may also result in avoidance behaviors, leading to muscle deconditioning and further functional impairment. Chronic hyperalgesia thus represents not only a sensory disorder but also a multidimensional health challenge that requires comprehensive management.

Diagnosis

Clinical Evaluation and History

The diagnosis of hyperalgesia begins with a comprehensive clinical assessment and patient history. Physicians evaluate the onset, nature, and distribution of pain, as well as any underlying conditions such as injury, surgery, or chronic inflammation. Questions related to medication use, particularly opioids, are crucial for identifying opioid-induced hyperalgesia. Physical examination focuses on the sensory profile of the affected region, comparing pain thresholds and responses between different body areas.

Quantitative Sensory Testing (QST)

Quantitative Sensory Testing is a standardized method used to evaluate the sensory and pain thresholds of patients. It employs calibrated stimuli such as heat, cold, mechanical pressure, or pinpricks to quantify pain perception. QST helps in differentiating between peripheral and central sensitization mechanisms by analyzing pain response patterns. Elevated pain intensity to thermal or mechanical stimuli provides objective evidence of hyperalgesia and helps monitor therapeutic outcomes over time.

Neurophysiological Assessments

Electrophysiological techniques such as laser-evoked potentials (LEPs) and nociceptive reflex testing are used to assess the function of pain pathways. These tests measure neural activity in response to specific nociceptive stimuli, providing insight into central processing abnormalities. Abnormalities in latency or amplitude of pain-related responses can indicate altered central excitability consistent with hyperalgesic states.

Imaging Studies

Advanced neuroimaging techniques like functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) have enhanced understanding of hyperalgesia. These tools visualize brain regions involved in pain modulation, including the thalamus, anterior cingulate cortex, and insula. Increased activation in these areas during painful stimulation indicates enhanced central processing of pain signals. Such imaging not only aids in diagnosis but also contributes to research into the neurobiology of pain hypersensitivity.

Differential Diagnosis

Hyperalgesia must be distinguished from other forms of abnormal pain perception to ensure accurate diagnosis and treatment. The following table summarizes the key differences between hyperalgesia, allodynia, and neuropathy:

Feature	Hyperalgesia	Allodynia	Neuropathy
Stimulus Type	Painful stimulus causes exaggerated pain	Non-painful stimulus causes pain	May involve spontaneous pain without external stimulus
Pathophysiology	Peripheral or central sensitization	Central sensitization and altered sensory processing	Nerve damage or degeneration
Common Causes	Inflammation, injury, opioid use	Fibromyalgia, central pain syndromes	Diabetes, trauma, infections
Diagnostic Approach	QST, clinical examination	QST, sensory mapping	Nerve conduction studies, EMG

Management and Treatment

Pharmacological Management

The treatment of hyperalgesia aims to reduce pain sensitivity and restore normal sensory processing. Pharmacological approaches target both peripheral and central mechanisms contributing to the exaggerated pain response. The choice of medication depends on the underlying cause, severity of pain, and patient-specific factors.

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs such as ibuprofen and diclofenac inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby decreasing peripheral sensitization. They are particularly effective in inflammation-associated hyperalgesia.
• Anticonvulsants: Drugs like gabapentin and pregabalin modulate calcium channel activity and reduce excitatory neurotransmitter release, making them effective for neuropathic and central pain syndromes.
• Antidepressants: Tricyclic antidepressants (e.g., amitriptyline) and serotonin-norepinephrine reuptake inhibitors (SNRIs) enhance descending inhibitory control and are beneficial in chronic hyperalgesic states.
• NMDA Receptor Antagonists: Medications such as ketamine block NMDA receptor activity, reducing central sensitization and mitigating opioid-induced hyperalgesia.
• Opioid Rotation or Tapering: In cases of opioid-induced hyperalgesia, reducing the opioid dose or switching to a different analgesic can help restore normal pain sensitivity.

Non-Pharmacological Therapies

Non-drug interventions play a vital role in managing hyperalgesia, particularly in chronic cases where pharmacological therapy alone is insufficient. These approaches aim to desensitize the nervous system, improve functional capacity, and enhance quality of life.

• Physical Therapy: Graded exercise, stretching, and desensitization techniques help maintain muscle strength, prevent stiffness, and normalize sensory thresholds.
• Cognitive-Behavioral Therapy (CBT): CBT addresses maladaptive thoughts and emotional responses to pain, helping patients develop effective coping mechanisms.
• Transcutaneous Electrical Nerve Stimulation (TENS): TENS provides low-level electrical stimulation that modulates pain transmission by activating inhibitory pathways in the spinal cord.
• Mind-Body Techniques: Practices such as mindfulness meditation, yoga, and deep-breathing exercises can lower stress-related amplification of pain perception and support relaxation.

Prevention Strategies

Opioid Use Management

Preventing hyperalgesia involves careful regulation of opioid administration, as prolonged or high-dose use can paradoxically increase pain sensitivity. Clinicians should employ multimodal analgesia, combining non-opioid drugs with physical and psychological therapies to minimize opioid dependence. When opioids are necessary, using the lowest effective dose and implementing rotation strategies can help prevent opioid-induced hyperalgesia. Regular monitoring and gradual tapering are essential to avoid neuroadaptive changes that enhance pain perception.

Early Intervention in Chronic Pain

Timely management of acute pain and inflammation is key to preventing chronic hyperalgesic states. Early interventions such as adequate analgesia, nerve blocks, and anti-inflammatory medications can reduce nociceptor sensitization. Prompt treatment of musculoskeletal injuries and neuropathic conditions prevents central sensitization, which is often irreversible once established. Patient education on pain management and realistic recovery expectations also plays a critical preventive role.

Inflammation Control and Lifestyle Modifications

Chronic systemic inflammation is a significant risk factor for persistent hyperalgesia. Lifestyle modifications such as balanced nutrition, weight management, and regular physical activity can reduce inflammatory burden. Dietary patterns rich in omega-3 fatty acids, antioxidants, and low in processed sugars support anti-inflammatory pathways. Adequate sleep, stress management, and smoking cessation further enhance neural health and reduce pain hypersensitivity risk.

Prognosis and Complications

Course of the Condition

The prognosis of hyperalgesia varies widely depending on the underlying cause and duration. In cases where peripheral sensitization is dominant, such as postoperative inflammation, symptoms may resolve once the tissue heals and mediators subside. However, in conditions involving central sensitization, pain can persist for months or years even after the original injury has healed. Early diagnosis and appropriate treatment significantly improve recovery outcomes.

Factors Influencing Recovery

Several factors determine the trajectory of hyperalgesia recovery, including:

• Etiology: Pain related to reversible inflammation resolves faster than that due to nerve injury or opioid exposure.
• Duration of Sensitization: Prolonged central sensitization leads to more persistent pain.
• Psychological Factors: Anxiety, depression, and catastrophizing behaviors can worsen pain perception and delay recovery.
• Therapeutic Compliance: Adherence to pharmacologic and rehabilitative interventions promotes better long-term outcomes.

Potential for Chronic Pain Development

Untreated or poorly managed hyperalgesia may progress into chronic pain syndromes due to long-lasting alterations in neural circuits. Continuous nociceptive input reinforces maladaptive plasticity within the spinal cord and brain, leading to persistent pain even in the absence of ongoing injury. This transition marks the evolution from acute nociceptive pain to maladaptive chronic pain, which is difficult to reverse. Addressing hyperalgesia early prevents this shift and preserves normal pain modulation mechanisms.

Associated Complications

Persistent hyperalgesia can give rise to several complications that extend beyond pain itself. Common consequences include:

• Functional Impairment: Restricted mobility, muscle weakness, and reduced endurance due to pain avoidance behaviors.
• Sleep Disturbances: Continuous pain interferes with sleep quality, exacerbating fatigue and irritability.
• Emotional and Cognitive Effects: Chronic pain often leads to anxiety, depression, memory impairment, and decreased concentration.
• Dependence on Analgesics: Repeated use of pain medications, especially opioids, may lead to tolerance, dependence, or drug-induced hyperalgesia.

These complications underline the necessity for multidisciplinary management, integrating pharmacological, psychological, and physical therapy interventions to improve overall patient well-being.

Recent Research and Advances

Novel Therapeutic Targets

Recent advancements in pain research have identified multiple molecular and cellular pathways that contribute to hyperalgesia, offering promising therapeutic targets. Investigations into ion channel modulation, particularly involving TRPV1, Nav1.7, and ASIC channels, have led to the development of selective blockers that reduce nociceptor excitability. Additionally, targeting neuroinflammation through inhibition of cytokines such as TNF-α and IL-1β has shown potential in reducing peripheral and central sensitization. New pharmacological compounds that modulate glial activity are also being explored to control neuroimmune interactions responsible for chronic pain amplification.

Genetic and Molecular Insights

Genomic and proteomic studies have deepened the understanding of hyperalgesia at a molecular level. Variations in genes encoding sodium channels, glutamate receptors, and pain-related signaling proteins influence individual susceptibility to hyperalgesia. Researchers are also studying the role of epigenetic modifications in chronic pain states, where DNA methylation and histone acetylation alter the expression of pain-related genes. These discoveries pave the way for personalized pain management strategies based on genetic profiling.

Advances in Neuroimaging and Biomarker Studies

Modern neuroimaging techniques have revolutionized the visualization of pain processing in the brain. Functional MRI (fMRI) and PET scans allow researchers to map brain activity associated with hyperalgesia, identifying hyperactive regions such as the anterior cingulate cortex and insular cortex. Biomarker research has also gained momentum, with specific inflammatory mediators, neuropeptides, and glial markers being investigated as diagnostic or prognostic indicators. Such advances enhance diagnostic precision and provide measurable endpoints for evaluating treatment efficacy in clinical trials.

Emerging Non-Pharmacological Approaches

Cutting-edge non-drug interventions are being studied to modulate pain perception and neuroplasticity. Techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) show potential in rebalancing cortical excitability and reducing central sensitization. Virtual reality–based distraction therapy and biofeedback systems are also being implemented as adjuncts to conventional pain treatment, demonstrating positive outcomes in reducing hyperalgesic symptoms without pharmacological side effects.

Clinical Significance

Implications for Pain Management

Understanding hyperalgesia is essential for improving pain management strategies across clinical disciplines. Recognition of sensitization mechanisms allows clinicians to tailor treatments that target both peripheral and central components of pain. Incorporating multimodal analgesia—combining pharmacologic agents with physical and behavioral therapies—yields superior outcomes compared to single-modality approaches. Awareness of opioid-induced hyperalgesia also guides safer prescribing practices and enhances patient safety.

Impact on Healthcare Systems

Hyperalgesia contributes significantly to the global burden of chronic pain, increasing healthcare utilization and costs. Patients with hyperalgesia often undergo repeated consultations, diagnostic tests, and medication adjustments. Effective early management can reduce these long-term costs by preventing chronic pain transitions. Health systems are increasingly focusing on interdisciplinary pain management clinics, integrating physicians, physiotherapists, and psychologists to provide comprehensive care.

Patient Education and Multidisciplinary Care

Educating patients about the mechanisms of hyperalgesia fosters better understanding and adherence to treatment plans. Counseling on realistic pain expectations, activity pacing, and the importance of maintaining mobility helps prevent fear-avoidance behaviors. Multidisciplinary approaches that incorporate physical rehabilitation, cognitive-behavioral therapy, and pharmacological management are essential to address the sensory, emotional, and social aspects of hyperalgesia. This holistic strategy not only alleviates pain but also enhances overall quality of life.

Through ongoing research, improved diagnostics, and integrative care models, the management of hyperalgesia continues to evolve, offering new hope for individuals suffering from heightened pain sensitivity and its far-reaching consequences.

References

1. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–S15.
2. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. Journal of Pain. 2009;10(9):895–926.
3. Bennett DLH, Woods CG. Painful and painless channelopathies. Lancet Neurology. 2014;13(6):587–599.
4. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain. 1995;62(3):259–274.
5. Baron R, Binder A, Wasner G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurology. 2010;9(8):807–819.
6. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Annual Review of Neuroscience. 2009;32:1–32.
7. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161.
8. Taylor BK, Corder G. Endogenous analgesia, dependence, and latent pain sensitization. Current Opinion in Behavioral Sciences. 2014;26:76–87.
9. Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiological Reviews. 2009;89(2):707–758.
10. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: Specificity and plasticity of the brain in clinical chronic pain. Physiological Reviews. 2011;91(4):1195–1246.